Impact of therapeutics on immune responses
Research type
Research Study
Full title
Impact of potential therapeutic agents on immunological responses
IRAS ID
354288
Contact name
Omar Qureshi
Contact email
Sponsor organisation
Celentyx Ltd.
Duration of Study in the UK
4 years, 11 months, 31 days
Research summary
Sometimes the human immune system can become dysregulated leading to overactive, misplaced, or insufficient immune responses. The development and progression of many inflammatory conditions, autoimmune disease, and cancer is tightly connected, but treatments designed to modulate the immune system and restore homeostasis remain non-curative. Therefore, there remains immense potential for the development of more efficient immunomodulatory treatments.
This is a 5-year study laboratory-based study limited to working with blood and tissue samples collected from individuals suffering from inflammatory conditions, autoimmune disease, or cancer. Using a variety of techniques and in vitro cell-based assays, the impact made by new compounds on the function and behaviour of immune responses will be investigated. The compounds under investigation may include new, existing, stalled, or repurposed drugs.
The research team do not plan to collect samples themselves but will obtain specimens from reputable commercial organisations. The study will be conducted under the direction of the Chief Investigator within research laboratories at Celentyx Ltd., Birmingham, UK.
REC name
London - Bloomsbury Research Ethics Committee
REC reference
25/PR/1229
Date of REC Opinion
26 Sep 2025
REC opinion
Favourable Opinion